Anemia and erythropoietin in cardiovascular disease
Kleijn, Lennaert

IMPORTANT NOTE: You are advised to consult the publisher's version (publisher's PDF) if you wish to cite from it. Please check the document version below.

Document Version
Publisher's PDF, also known as Version of record

Publication date:
2014

Link to publication in University of Groningen/UMCG research database

Citation for published version (APA):

Copyright
Other than for strictly personal use, it is not permitted to download or to forward/distribute the text or part of it without the consent of the author(s) and/or copyright holder(s), unless the work is under an open content license (like Creative Commons).

Take-down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately and investigate your claim.

Downloaded from the University of Groningen/UMCG research database (Pure): http://www.rug.nl/research/portal. For technical reasons the number of authors shown on this cover page is limited to 10 maximum.
Impact of postoperative anemia on cardiovascular outcome after Coronary artery bypass graft surgery; insights from the IMAGINE trial

B. Daan Westenbrink
Lennaert Kleijn
Rudolf A. de Boer
Wayne J. Warnica
Richard Baillot
R. Mark Iwanochko
Jean L. Rouleau
Wieck H. van Gilst
Abstract

Objective
To investigate the association between sustained postoperative anaemia and outcome after coronary artery bypass graft (CABG) surgery.

Design
Retrospective analysis of the IMAGINE trial, which tested the effect of the ACE inhibitor quinapril on cardiovascular events after CABG.

Setting
Thoracic surgery clinic/outpatient department. Patients 2553 stable patients with left ventricular ejection fraction >40% 2-7 days after scheduled CABG.

Interventions
Randomisation to quinapril or placebo. Main outcome measures Cox regression analysis for the association between postoperative anaemia and cardiovascular events and the effect of quinapril on the incidence of anaemia.

Results
Postoperative anaemia was sustained for >50 days in 44% of patients. Sustained postoperative anaemia was associated with an increased incidence of cardiovascular events during the first 3 months (adjusted HR (adjHR) 1.77, 95% CI 1.10 to 2.85, p=0.012) and during the maximum follow-up of 43 months (adjHR 1.37, 95% CI 1.14 to 1.65, p=0.008). When haemoglobin (Hb) was considered as a continuous variable, every 1 mg/dl decrease in Hb was associated with a 13% increase in cardiovascular events (adjHR 0.87, 95% CI 0.81 to 0.95, p=0.003) and a 22% increase in all-cause mortality (adjHR 0.78, 95% CI 0.60 to 0.99, P=0.034). Quinapril was associated with a slower postoperative recovery of Hb levels and a higher incidence of cardiovascular events in patients with anaemia (adjHR 1.60, 95% CI 1.1 to 2.4, p=0.024).

Conclusions
Postoperative anaemia is common, frequently persists for months after CABG surgery and is associated with an impaired outcome. In patients with anaemia, ACE inhibitors slowed recovery from postoperative anaemia and increased the incidence of cardiovascular events after CABG.
Introduction

Anaemia is a well-established predictor of impaired cardiovascular outcome in patients with coronary artery disease, acute coronary syndromes, chronic heart failure as well as in the general population. In addition, the presence of anaemia before cardiac and non-cardiac surgery and during extracorporeal bypass predicts postoperative cardiovascular events. The consistent association between anaemia and cardiovascular events suggests that the severity and duration of postoperative anaemia should be limited in patients undergoing coronary artery bypass graft (CABG) surgery. There are, however, several reasons to suspect a high incidence of anaemia after CABG that may often persist for months after discharge. First, blood loss during CABG surgery is common owing to the nature and extent of the surgery and also because of required heparinisation and additional acquired defects in haemostasis during on-pump procedures. Second, during on-pump procedures anaemia is often induced in patients by mild euvoaemic haemodilution. Third, blood transfusions are deliberately avoided because they have been linked to impaired survival after CABG. If a substantial proportion of patients remain anaemic for an extended period after CABG, this would suggest that patients are subjected to an established cardiovascular risk factor by an intervention that is intended to reduce that risk. Although the impact of preoperative anaemia and perioperative transfusions have been addressed extensively, the incidence of sustained postoperative anaemia and its impact on the outcome after CABG is unclear. We hypothesised that sustained postoperative anaemia after CABG surgery is common and associated with an increased incidence of cardiovascular events. In order to test our hypothesis we used the contemporary IMAGINE (Ischaemia Management with Acupril post bypass Graft via Inhibition of thecoNverting Enzyme) trial database of 2553 patients with preserved left ventricular function undergoing CABG. Because ACE inhibitors have the capacity to reduce erythropoiesis activity and might increase the incidence and duration of sustained postoperative anaemia, we also evaluated the effects of quinapril on postoperative anaemia.

Methods

Design

The design of the IMAGINE trial has been described in detail previously, as well as the results of the main study. In brief, the IMAGINE study was a double-blind placebo-controlled parallel-group randomised multicentre international trial conducted in
patients who underwent CABG surgery between November 1999 and September 2004. The main goal of the study was to test whether early initiation of ACE inhibitor therapy (initiated within the hospital phase) after CABG would reduce the rate of cardiovascular events in patients at relative low risk. The research protocol was approved by the ethics committees of all participating institutions and all patients provided written informed consent.

Patients
Patients were screened for eligibility within 4 weeks of surgery or following surgery and randomised within 7 days after CABG, except for patients included in France (N=235, 9.1%) where randomisation occurred within 10 days after CABG. Treatment consisted of the ACE inhibitor quinapril, with forced uptitration to 40 mg daily within 4 months if tolerated, or matching placebo. The final sample size of the IMAGINE study was 2553 patients.

Anaemia
Anaemia was defined according to the WHO criteria (haemoglobin (Hb) <13.0 g/dl in men and Hb <12.0 g/dl in women). We explored the temporal characteristics of anaemia in the entire IMAGINE population. For outcome analysis, patients were classified into two groups: those with sustained anaemia at 50 days after randomisation (anaemic group) and those in whom Hb levels had recovered to normal values during that period (non-anaemic group). Because the definition of anaemia represents a relatively arbitrary Hb cut-off, we also evaluated the effects of Hb as a continuous variable at 50 days after randomisation. Because our analysis was focused on sustained postoperative anaemia, we excluded patients with normal Hb levels at randomisation and patients without documented Hb levels at 50 days (leaving 2400 subjects).

Endpoints
We used the same primary and secondary endpoints as in the IMAGINE trial, including an additional composite endpoint of major adverse cardiac events (MACE), and we also considered all individual endpoints separately. The primary endpoint was a composite of cardiovascular death or resuscitated cardiac arrest, non-fatal myocardial infarction, coronary revascularisation, unstable angina requiring hospitalisation, documented angina not requiring hospitalisation, stroke and congestive heart failure (CHF) requiring hospitalisation. The pre-specified secondary endpoint was a composite of the primary endpoint with the addition of transient ischaemic attack and any other cardiovascular
event requiring hospitalisation. MACE was defined as cardiovascular death or resuscitated cardiac arrest, acute coronary syndromes, coronary revascularisation and CHF requiring hospitalisation. Because we expected that postoperative anaemia would predominantly affect the early postoperative phase, we also separately evaluated the effect of sustained postoperative anaemia on the primary IMAGINE endpoint during and after the first 3 months of the study.

**Statistical analysis**

Data are shown as mean ± SD when normally distributed, as median (IQR) in cases of skewed distribution and as frequencies and percentages for categorical variables. Differences in variables between groups were compared with the Student t test, the Mann-Whitney U test, $\chi^2$ test or Fisher exact test, where appropriate. Time to the first event was calculated from 50 days onward, except for the analysis of the first 3 months where time to first event was calculated from randomisation. Temporal changes in Hb levels and the incidence of anaemia were compared using ANCOVA for repeated measurements. Differences between the anaemic and non-anaemic groups, use of Hb as a continuous variable and the effect of quinapril treatment were estimated as a HR with associated adjusted two-sided 95% CI from a Cox proportional hazards regression model that included the effects of age, gender, treatment assignment, country, transfusions, number of days after CABG surgery, cardiac medications, baseline Hb levels, left ventricular ejection fraction (LVEF), smoking status, systolic and diastolic blood pressure and creatinine values at baseline or at 50 days after randomisation, history of hypertension/diabetes/percutaneous coronary interventions/myocardial infarction/previous CABG surgery/peripheral vascular disease and stroke, vessel disease, number of distal anastomoses, completeness of revascularization (defined as complete when all vessels >1 mm with a stenosis >70% were bypassed) and beating heart (off pump) surgery.

Cumulative event rates were calculated by the Kaplan-Meier method and displayed graphically. Differences in the incidence of the component endpoints within or after the first 3 months were assessed by univariate logistic regression analysis. All statistical analyses were performed using SPSS Version 17.0.

**Results**

**Incidence of anaemia**

Patients were randomised an average of 462 days after CABG surgery. During randomisation, 2400 patients (94%) were anaemic according to the WHO criteria for anaemia
and 444 (19%) had Hb values <9 mg/dl. However, only 11 (3%) of the patients with Hb levels <9 mg/dl received a blood transfusion during the first 10 days after randomisation. Hb levels increased steadily during the first year (figure 1), at which point 163 (8%) of the patients were still anaemic (figure 1). Hb levels and the proportion of anaemic subjects remained constant after 1 year (figure 1). Throughout the study period anaemia was reported as an adverse event in 140 patients (6%). In 30 patients (1.2%), diagnostic or therapeutic measures were taken in response to anaemia. Blood transfusions were given to 21 patients (0.8%) during the entire study period. Of the 13 patients who received a blood transfusion within the first 50 days after randomisation, nine had recovered from anaemia at 50 days.

Demographic characteristics of the study population

The characteristics of the study group are given in table 1. At the visit 50 days after randomisation, 967 (44%) of the 2180 patients with anaemia at baseline and available Hb levels at 50 days were still anaemic. Patients with sustained postoperative anaemia were significantly older, had a higher incidence of previous CABG surgery and were more often current smokers. Anaemic patients had a higher incidence of anaemia at randomisation, lower red blood cell, white blood cell and platelet counts and significantly higher creatinine values. Preoperative LVEF was comparable between anaemic and non-anaemic patients with CHF, but systolic and diastolic blood pressures were
Table 1. Demographics of the study population at 50 days after randomization according to the presence of sustained postoperative anemia

<table>
<thead>
<tr>
<th>Variable</th>
<th>Non-anemic (n=1327)</th>
<th>Anemic (n=988)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age</td>
<td>59 ± 10</td>
<td>63 ± 9</td>
<td>0.0001</td>
</tr>
<tr>
<td>Female, n (% of patients)</td>
<td>164 (12)</td>
<td>117 (12)</td>
<td>0.748</td>
</tr>
<tr>
<td>White, n (% of patients)</td>
<td>1278 (96)</td>
<td>949 (96)</td>
<td>0.741</td>
</tr>
<tr>
<td>Acupril group, n (% of patients)</td>
<td>637 (48)</td>
<td>505 (51)</td>
<td>0.110</td>
</tr>
<tr>
<td>Anemia at baseline, n (% of patients)</td>
<td>1213 (92)</td>
<td>967 (98)</td>
<td>0.0001</td>
</tr>
<tr>
<td>Days after CABG surgery, Mean ± SD</td>
<td>24 (2)</td>
<td>24 (2)</td>
<td>0.661</td>
</tr>
</tbody>
</table>

Medical History, n (% of patients)

- Previous MI
- Previous Stroke
- Previous CABG
- Previous PCI
- Diabetes
- History of hypertension
- Current smoker

<table>
<thead>
<tr>
<th>Laboratory values, Mean ± SD</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Hemoglobin (mg/dL)</td>
<td>14 ± 0.8</td>
<td>12 ± 0.8</td>
<td>-</td>
</tr>
<tr>
<td>RBC (x10^{12}/L)</td>
<td>4.7 ± 0.035</td>
<td>4.1 ± 0.36</td>
<td>&gt;0.0001</td>
</tr>
<tr>
<td>White blood count (x10^{9}/L)</td>
<td>7.2 ± 2</td>
<td>7.0 ± 2</td>
<td>0.064</td>
</tr>
<tr>
<td>Platelets (x10^{9}/L)</td>
<td>292 ± 83</td>
<td>270 ± 68</td>
<td>&gt;0.0001</td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)</td>
<td>4.9 ± 1</td>
<td>4.8 ± 1</td>
<td>0.372</td>
</tr>
<tr>
<td>LDL cholesterol (mmol/L)</td>
<td>2.9 ± 1</td>
<td>23 ± 52</td>
<td>0.263</td>
</tr>
<tr>
<td>HDL cholesterol (mmol/L)</td>
<td>1.1 ± 0.3</td>
<td>1.1 ± 0.4</td>
<td>0.811</td>
</tr>
<tr>
<td>Creatinine (µmol/L)</td>
<td>88 ± 17</td>
<td>90 ± 19</td>
<td>&gt;0.0001</td>
</tr>
</tbody>
</table>

Hemodynamic measurements, Mean ± SD

- LVEF (%)
- Systolic blood pressure (mmHg)
- Diastolic blood pressure (mmHg)

<table>
<thead>
<tr>
<th>Operative characteristics</th>
<th></th>
<th></th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td>Beating heart surgery, n (% of patients)</td>
<td>264 (20)</td>
<td>171 (17)</td>
<td>0.119</td>
</tr>
<tr>
<td>Number of distal anastomosis, Mean±SD</td>
<td>3.2 ± 1.2</td>
<td>3.3 ± 1.1</td>
<td>0.023</td>
</tr>
<tr>
<td>Vessel disease, Mean ± SD</td>
<td>2.5 ± 0.7</td>
<td>2.6 ± 0.6</td>
<td>0.003</td>
</tr>
<tr>
<td>Complete revascularization, n (% of patients)</td>
<td>723 (55)</td>
<td>523 (53)</td>
<td>0.448</td>
</tr>
</tbody>
</table>

Baseline medications, n (% of patients)

- Beta blocker
- Calcium channel inhibitor
- Angiotensin receptor blocker
- Platelet inhibitor
- Statin
- Diuretic

SD, standard deviation; MI, myocardial infarction; CABG, coronary artery bypass graft surgery; PCI, percutaneous coronary intervention; RBC, red blood cell count; LDL, low density lipoprotein; HDL, High density lipoprotein; LVEF, left ventricular ejection fraction.
significantly lower in the patients with anaemia. Anaemic patients more often had multivessel disease. There was no difference in the number of distal anastomoses or incomplete revascularisations between the groups. Finally, baseline medication was comparable between anaemic and non-anaemic patients.

**Events**

The median follow-up time was 1082 days (IQR 160e1323). Univariate differences in events according to the presence of sustained postoperative anaemia are shown in table 2. Anaemia resulted in a 77% increase in the primary endpoint within the first 3 months after randomisation (adjusted HR (adjHR) 1.77, 95% CI 1.10 to 2.85, p=0.012, table 2, figure 2). After 3 months the incidence of the different endpoints was comparable between groups (data not shown). Anaemia did not affect the incidence of the primary endpoint after 50 days. However, the incidence of the secondary IMAGINE endpoint and MACE were both increased by 40% in patients with anaemia (table 3, figure 3). When analysed as a continuous variable, lower Hb levels were also associated with an impaired outcome after CABG (table 3). In fact, every decrease in Hb of 1 mg/dl was associated with a 13% increase in the incidence of the secondary endpoint and MACE and a 22% increase in all cause death or resuscitated cardiac arrest (table 3). The primary endpoint was not associated with continuous Hb levels.

**Effect of quinapril on postoperative anaemia**

Hb levels were identical at baseline in patients randomized to quinapril and placebo (10.43 ± 61.45 vs 10.41 ± 61.45 mg/dl, p=0.783). Similarly, the proportion of anaemic patients was similar at baseline in the quinapril and placebo groups (1198 (94%) vs 1202 (95%), p=0.796). The proportion of patients with diabetes was comparable between the quinapril and placebo groups and background medications were also comparable (data not shown). After randomisation, recovery of Hb levels was slower in patients randomised to quinapril than in those receiving placebo and remained lower in the quinapril group throughout the follow-up period (figure 4A). Similarly, a higher proportion of patients remained anaemic in the quinapril group than in the placebo group throughout the follow-up period (figure 4A).

**Effect of quinapril on outcome in anaemic patients**

In the subgroup of patients who were anaemic at randomisation, 99 patients (4.1%) experienced a primary endpoint during the first 3 months, 61 (5.1%) in the quinapril group and 38 (3.2%) in the placebo group (HR 1.62, 95% CI 1.1 to 2.4, figure 4B). A sec-
Table 2. Univariate and multivariate hazard ratios for primary and secondary endpoints

<table>
<thead>
<tr>
<th>Endpoints</th>
<th>Persistent anemia</th>
<th>Hemoglobin continuous</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Unadjusted HR (95% CI)</td>
<td>Adjusted † HR(95% CI)</td>
</tr>
<tr>
<td>Primary composite</td>
<td></td>
<td></td>
</tr>
<tr>
<td>- First 3 months</td>
<td>1.19 (0.95-1.50)</td>
<td>1.16 (0.91-1.49)</td>
</tr>
<tr>
<td>- After 3 months</td>
<td>1.94 (1.04-3.02)*</td>
<td>1.78 (1.10-2.87)*</td>
</tr>
<tr>
<td>Secondary composite</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>1.30 (1.08-1.57)*</td>
<td>1.32 (1.08-1.61)*</td>
</tr>
</tbody>
</table>

HR, hazard ratio; CI, confidence intervals; †; Adjusted for, age, gender, treatment assignment, country, days after CABG-surgery, transfusions, left ventricular ejection fraction, systolic and diastolic blood pressure, creatinine, history of hypertension / diabetes / percutaneous coronary interventions / myocardial infarction / previous CABG surgery / peripheral vascular disease / stroke, number of distal anastomosis, completeness of revascularization and beating heart (off pump) surgery, ‡; also adjusted for baseline hemoglobin levels. *, P<0.05; #, P<0.005; §, P<0.0005

A secondary event was experienced in 102 (43%) patients, 62 (5.2%) in the quinapril group and 40 (3.3%) in the placebo group (HR 1.57, 95% CI 1.1 to 2.3, p=0.026). Quinapril significantly increased the incidence of the primary and secondary endpoints during the first 3 months. It did not affect the incidence of the primary and secondary endpoints after 3 months, nor did it affect the outcome when the entire study period was considered (data not shown).

Discussion
In this study we show for the first time that sustained postoperative anaemia after CABG surgery is associated with an impaired outcome. Although some degree of mild to moderate anaemia might be expected in the immediate postoperative period, we show that postoperative anaemia is the rule rather than the exception, is frequently severe and often persists for months in a substantial proportion of patients. Moreover, anaemia generally seems to be regarded as a benign condition, as it was sparsely reported as an adverse event and only very few patients were diagnosed or treated in our contemporary population. In this study we show that sustained postoperative anaemia may not be benign, but is rather associated with an impaired outcome even in low-risk patients. In addition, we show that the initiation of an ACE inhibitor in the early postoperative phase after CABG slows postoperative recovery of Hb levels and is associated with an increase in early cardiovascular events. We therefore propose that more aggressive measures to prevent or limit postoperative anaemia and perioperative discontinuation of ACE inhibitors could improve the outcome after CABG.
Chapter 4

Incidence, aetiology and impact of sustained postoperative anaemia

The few studies that have addressed the impact of postoperative anaemia on outcome in patients undergoing CABG surgery were restricted to the immediate postoperative ICU period. One of the most surprising findings of our study is that it frequently takes months to recover from anaemia after CABG, even in a low-risk population with few co-morbidities. Similar to other cardiac populations, the aetiology of anaemia after CABG surgery is likely to be multifactorial including perioperative blood loss, haemodilution, bone marrow depression and persisting preoperative causes for anaemia such as haematinic deficiencies or renal dysfunction. Despite its high incidence, anaemia was documented as an adverse event in only 6%, and diagnosed and treated in only 1% of anaemic patients. These findings strongly suggest that anaemia is not considered as an important comorbidity after CABG. However, we clearly show that sustained anaemia is associated with a marked increase in cardiovascular events. In our opinion, postoperative anaemia should therefore not be regarded as a benign condition and increased awareness of the importance of anaemia after cardiac surgery is thus warranted. Effect

Figure 2. Kaplan-Meier analysis of event free survival of the primary endpoint during the first 3 months according to the presence or absence of sustained postoperative anaemia. Primary composite endpoint of the IMAGINE trial comprising time to first occurrence of cardiovascular death or resuscitated cardiac arrest, nonfatal myocardial infarction, coronary revascularization, unstable angina that required hospitalization, documented angina that did not require hospitalization, stroke and congestive heart failure that required hospitalization. HR, Hazard Ratio; 95% CI, 95 percent confidence interval.
of ACE inhibitors on postoperative anaemia. ACE inhibitors reduce erythropoiesis in patients with heart failure through increased levels of N-acetyl-ser-aryl-aspartyl-lysylproline, a haematopoiesis inhibitor exclusively depredated by ACE. Moreover, a small Italian study showed that enalapril slowed postoperative recovery of Hb levels when given early after CABG. In our analysis, the early initiation of quinapril after CABG slowed recovery of Hb levels and was also associated with early cardiovascular events. Due to the expanding indications for ACE inhibitors in patients with coronary artery disease, a large number of patients scheduled for CABG surgery will be treated with these drugs. Importantly, a recent retrospective study of 10 000 British patients undergoing CABG surgery showed that ACE inhibitors are often continued during surgery or re-initiated early after CABG. Furthermore, the authors showed that preoperative treatment with an ACE inhibitor was linked to increased mortality. Our finding that quinapril increased early cardiovascular events when given to anaemic patients in the early postoperative phase suggests that the detrimental effects of perioperative ACE inhibitor therapy can in part be explained by the delayed recovery of Hb levels.

Table 3. Incidence of the primary and secondary endpoints and their components during the first 3 months after randomization

<table>
<thead>
<tr>
<th>Variable</th>
<th>Non-anemic (n=1327)</th>
<th>Anemic (n=988)</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary composite endpoint</td>
<td>33 (2.5)</td>
<td>47 (4.8)</td>
<td>0.004</td>
</tr>
<tr>
<td>Cardiovascular death or resuscitated cardiac arrest</td>
<td>1 (0.1)</td>
<td>1 (0.1)</td>
<td>1.000</td>
</tr>
<tr>
<td>Non-fatal myocardial infarction</td>
<td>3 (0.2)</td>
<td>3 (0.3)</td>
<td>0.705</td>
</tr>
<tr>
<td>Unstable angina requiring hospitalization</td>
<td>7 (0.5)</td>
<td>11 (1.1)</td>
<td>0.150</td>
</tr>
<tr>
<td>Documented angina not requiring hospitalization</td>
<td>20 (1.5)</td>
<td>15 (1.5)</td>
<td>1.000</td>
</tr>
<tr>
<td>Coronary revascularisation</td>
<td>0 (0)</td>
<td>1 (0.1)</td>
<td>0.427</td>
</tr>
<tr>
<td>Stroke or TIA</td>
<td>0 (0)</td>
<td>2 (0.2)</td>
<td>0.182</td>
</tr>
<tr>
<td>CHF requiring hospitalization</td>
<td>2 (0.2)</td>
<td>11 (1.1)</td>
<td>0.003</td>
</tr>
<tr>
<td>Any other cardiovascular event</td>
<td>0 (0)</td>
<td>3 (0.3)</td>
<td>0.078</td>
</tr>
<tr>
<td>Cardiac ischemia composite endpoint *</td>
<td>31 (2.3)</td>
<td>31 (3.4)</td>
<td>0.244</td>
</tr>
<tr>
<td>Cardiac composite endpoint #</td>
<td>33 (2.5)</td>
<td>42 (4.5)</td>
<td>0.024</td>
</tr>
</tbody>
</table>

*Composite of cardiovascular death or resuscitated cardiac arrest, nonfatal myocardial infarction, coronary revascularization, unstable angina that required hospitalization, documented angina that did not require hospitalization. # Composite of the above with the addition of congestive heart failure requiring hospitalization; TIA, transient ischemic cerebrovascular attack; CHF, congestive heart failure.
Transfusions

Another important observation in our analysis was that blood transfusions were only sparsely administered, despite the high incidence of severe anaemia. While this approach is in accordance with current guidelines, it may in part explain the high incidence of sustained postoperative anaemia. Koch et al recently showed that the use of older blood products is associated with mortality after CABG, suggesting that the risks of transfusions are more related to the quality of the blood than the transfusion itself. Together these findings suggest that the balance between risk and benefit of transfusions after CABG should be reconsidered. Our study does not, however, address the safety and efficacy of blood transfusions after CABG surgery and we cannot recommend more lenient transfusions based on our retrospective study. A prospective evaluation is urgently awaited.

Limitations

Ideally, we would have liked to have data on the exact duration of postoperative anae-
Figure 4. Effect of Acupril on postoperative recovery of hemoglobin levels and the effect of Acupril on survival in patients with anemia. A. Temporal changes of hemoglobin levels and percentage of patients with anemia after coronary artery bypass graft surgery, in patients randomized to Acupril or placebo. B. Kaplan-Meier analysis of event free survival of the primary endpoint during the first 3 months according to treatment groups, namely Acupril or placebo. Primary composite endpoint of the IMAGINE trial comprised time to first occurrence of cardiovascular death or resuscitated cardiac arrest, nonfatal myocardial infarction, coronary revascularization, unstable angina that required hospitalization, documented angina that did not require hospitalization, stroke and congestive heart failure that required hospitalization. HR, Hazard Ratio; 95% CI, 95 percent confidence interval.
mia in all patients. Unfortunately, the frequency of Hb measurements in the IMAGINE protocol was fairly sparse and the first post-discharge Hb value was measured 50 days after randomisation. Early events that occurred while a patient was anaemic but in whom Hb had recovered at the 50-day post-randomisation visit were therefore attributed to the non-anaemic group. Therefore, the number of early events associated with the presence of anaemia is potentially underestimated in our analysis. Similarly, we cannot exclude the possibility that events that occurred before 50 days affected the duration of postoperative anaemia. This limitation should be borne in mind when interpreting the analysis of the early events. In addition, defining groups at 50 days after randomization excludes patients who died before 50 days. The IMAGINE study involved a relatively healthy low-risk population, so the deleterious effects of anaemia might be different in the general CABG population. Finally, despite the use of extensive multivariable adjustments, we cannot be certain that the relation between anaemia and events is causal since we employed a retrospective analysis of prospectively-collected data. Alternatively, sustained postoperative anaemia might be a marker for a high-risk subgroup of patients. Future studies are needed to further define the impact of postoperative anaemia on outcome after CABG surgery.

Clinical implications
Our study shows that the duration of postoperative anaemia is an important determinant of outcome after CABG. We therefore propose more aggressive measures to limit the severity and duration of postoperative anaemia. This could, for instance, be achieved by increased utilisation of contemporary strategies to limit the duration and severity of postoperative anaemia, such as minimal invasive surgery, autologous blood transfusions, thrombostatic drugs and perhaps erythropoiesis-stimulating proteins. It also seems logical to evaluate Hb levels early after discharge in order to identify and treat patients with sustained postoperative anaemia in an early phase. Furthermore, our data suggest that perioperative discontinuation of ACE inhibitors could prevent sustained postoperative anaemia. Prospective studies are required to determine whether these measures will reduce postoperative anaemia and improve the outcome after CABG surgery.

Conclusions
Postoperative anaemia is common, frequently persists for months after CABG surgery and is associated with an impaired cardiovascular outcome. ACE inhibitors slow postoperative recovery of Hb levels after CABG and increase cardiovascular events in pa-
Impact of postoperative anemia on cardiovascular outcome after Coronary artery bypass graft surgery

tients with anaemia.
Chapter 4

References


Impact of postoperative anemia on cardiovascular outcome after Coronary artery bypass graft surgery


